Eli Lilly’s Zepbound gains sleep apnea indication

by
Contributor since / Followers
12 hours ago
Mature man in bed sleeping on his back snoring with his mouth open

NicolasMcComber/iStock via Getty Images

  • The U.S. FDA has approved an additional indication for Eli Lilly’s (NYSE:LLY) Zepbound (tirzepatide) to include obstructive sleep apnea in obese adults.
  • The approval was based on results from a phase 3 trial that showed the drug benefitted individuals irregardless
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *